4D Molecular Therapeutics, Inc.

FDMT

4D Molecular Therapeutics, Inc.

FDMT

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-23Shares Purchased (TTM):0Shares Sold (TTM):139,655

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:47,249,850Shares Outstanding:68,064,586Institutional Ownership Pct.:69.42%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	70	72	60	49	77	134	149	188	189	276	249	276
Marketable Securities Current	291	318	342	257	216	188	276	314	353	250	39	44
Prepaid Expense And Other Assets Current	17	14	10	7	10	11	10	9	11	10	8	9
Assets Current	383	405	413	312	303	333	435	511	553	536	297	328
Marketable Securities Noncurrent	69	67	111	67	124	137	81	49	36	63	11	0
Property Plant And Equipment Net	12	14	15	16	18	19	20	20	19	19	20	21
Operating Lease Right Of Use Asset	17	17	18	19	20	20	21	22	11	11	12	12
Other Assets Noncurrent	11	10	9	9	9	7	4	3	2	1	1	1
Assets	493	513	567	424	474	516	560	604	620	630	340	362
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	13	15	11	7	9	4	4	3	3	4	4	5
Accrued Liabilities Current	25	23	27	24	19	16	19	21	13	9	12	10
Contract With Customer Liability Current	0	0	0	0	1	1	0	0	0	0	0	0
Operating Lease Liability Current	5	5	6	6	6	6	6	5	3	3	3	3
Liabilities Current	48	43	44	37	35	27	29	29	19	16	19	18
Contract With Customer Liability Noncurrent	3	2	1	1	0	0	1	1	1	1	1	1
Derivative Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	14	15	16	17	17	18	19	20	10	11	12	12
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	85	61	61	55	53	46	50	51	32	29	32	32
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,266	1,237	1,221	1,104	1,099	1,094	1,087	1,078	1,071	1,048	723	712
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	1	1	0	0	0	1	-0	-0	0	1
Retained Earnings Accumulated Deficit	-858	-785	-716	-736	-679	-624	-576	-527	-483	-448	-415	-383
Stockholders Equity	408	452	506	369	421	470	511	553	588	601	308	330
Liabilities And Stockholders Equity	493	513	567	424	474	516	560	604	620	630	340	362
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	55	52	58	47	47	46	46	52	52	51	43	43
Shares Outstanding	55	52	58	47	47	46	46	52	52	51	43	43

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.20%	16.82%	1.41%	-	-	-	-	-	-	-	-	-
2025	11.73%	18.52%	41.05%	31.46%	54.61%	107.96%	5.21%	-28.02%	-12.88%	14.60%	18.46%	0.93%
2024	-6.51%	-18.14%	-28.43%	1.90%	-26.48%	-44.67%	-4.67%	-23.09%	-27.37%	-13.47%	-32.45%	-24.06%
2023	-	-	-	-	-	-	26.48%	92.95%	66.67%	19.91%	-9.89%	-9.56%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	8.03	9.34	9.39	8.42	8.75	12.36	14.92	17.33	28.48	32.65	15.65	18.07
Quick Ratio	7.68	9.01	9.15	8.22	8.46	11.95	14.58	17.03	27.93	32.06	15.21	17.60
Working Capital	335.28M	361.96M	369.15M	275.27M	268.61M	305.67M	405.78M	481.29M	533.23M	519.19M	277.64M	310.08M
Leverage & Debt
Debt to Equity	0.21	0.14	0.12	0.15	0.13	0.10	0.10	0.09	0.05	0.05	0.10	0.10
Debt Ratio	0.17	0.12	0.11	0.13	0.11	0.09	0.09	0.08	0.05	0.05	0.09	0.09
Efficiency & Turnover
Asset Turnover TTM	0.19	0.17	0.15	0.00	0.00	0.00	0.00	0.00	0.04	0.05	0.07	0.07
Per Share Metrics
Diluted EPS TTM	-2.55	-2.36	-2.42	-3.73	-3.51	-3.17	-2.98	-2.58	-1.99	-2.12	-2.58	-2.27
Free Cash Flow Per Share TTM	-1.93	-1.91	-1.90	-2.45	-2.18	-2.82	-2.57	-2.10	-1.58	-1.61	-2.01	-1.81
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-214.24%	-203.47%	-187.24%	-191,982.50%	-667,654.55%	-884,026.09%	-507,678.38%	-935,416.67%	-648.98%	-591.10%	-544.65%	-477.22%
Net Profit Margin TTM	-194.74%	-182.34%	-164.43%	-174,314.17%	-594,375.76%	-767,126.09%	-434,778.38%	-797,111.11%	-543.51%	-511.20%	-486.59%	-436.28%
Growth Metrics
Net Revenue Growth (1Y)	278,712.12%	383,560.87%	230,194.59%	566.67%	-99.84%	-99.89%	-99.82%	-99.92%	784.86%	826.31%	562.29%	1,014.50%
Net Income Growth (1Y)	-8.65%	-8.81%	-12.90%	45.79%	78.49%	68.75%	59.53%	49.56%	-1.32%	-4.81%	-6.19%	-8.81%
EPS Growth (1Y)	-27.30%	-25.32%	-18.90%	44.30%	76.43%	49.16%	15.72%	13.76%	-31.57%	-36.78%	-22.44%	-30.11%
Valuation Metrics
P/E TTM	-5.22	-3.94	-3.10	-2.33	-1.06	-1.02	-1.87	-4.19	-10.56	-15.01	-7.86	-5.61
P/B TTM	2.29	1.40	0.86	1.32	0.49	0.38	0.59	1.09	1.97	2.61	2.58	1.63
P/S TTM	10.16	7.18	5.10	4,064.48	6,287.56	7,828.40	8,120.72	33,363.55	57.39	76.75	38.26	24.46
Market Cap	934.62M	633.68M	434.48M	487.74M	207.49M	180.05M	300.47M	600.54M	1.16B	1.57B	792.78M	537.93M
Enterprise Value	864.25M	561.19M	374.24M	439.18M	130.33M	46.53M	151.13M	413.00M	971.32M	1.29B	543.67M	262.25M
Calculated Values
Free Cash Flow TTM	-135.87M	-129.68M	-109.94M	-137.48M	-122.06M	-156.96M	-138.37M	-116.76M	-87.17M	-79.44M	-78.56M	-76.67M
Net Debt	-70.37M	-72.49M	-60.24M	-48.56M	-77.16M	-133.53M	-149.34M	-187.54M	-189.06M	-275.59M	-249.11M	-275.68M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Sale

Owner: Bizily, Scott

Title: Chief Legal Officer

Shares: 9,810

Price/Share: $12.00

Value: $117,720.00

Shares Owned: 8,617

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Kirn, David

Title: See Remarks

Shares: 114,746

Price/Share: $10.47

Value: $1,201,390.62

Shares Owned: 942,485

Relationship: Director,Officer

Ownership: Direct

2026-06-01Sale

Owner: Kirn, David

Title: See Remarks

Shares: 1,922

Price/Share: $10.02

Value: $19,258.44

Shares Owned: 1,057,231

Relationship: Director,Officer

Ownership: Direct

2026-03-20Sale

Owner: Gupta, Ashoo

Title: VP, Finance and Controller

Shares: 390

Price/Share: $8.61

Value: $3,357.90

Shares Owned: 46,914

Relationship: Officer

Ownership: Direct

2025-12-20Sale

Owner: Gupta, Ashoo

Title: VP, Finance and Controller

Shares: 389

Price/Share: $8.68

Value: $3,376.52

Shares Owned: 46,218

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	9,810	12.00	$117,720.00	8,617	4
2026-06-22	Kirn, David	Director,Officer	See Remarks	Direct	Sale	114,746	10.47	$1,201,390.62	942,485	4
2026-06-01	Kirn, David	Director,Officer	See Remarks	Direct	Sale	1,922	10.02	$19,258.44	1,057,231	4
2026-03-20	Gupta, Ashoo	Officer	VP, Finance and Controller	Direct	Sale	390	8.61	$3,357.90	46,914	4
2025-12-20	Gupta, Ashoo	Officer	VP, Finance and Controller	Direct	Sale	389	8.68	$3,376.52	46,218	4
2025-12-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,635	10.90	$17,821.50	3,594	4
2025-11-17	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,635	10.59	$17,314.65	3,594	4
2025-10-24	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	2,678	12.00	$32,136.00	3,594	4
2025-10-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,635	10.17	$16,627.95	5,188	4
2025-10-09	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	2,408	10.00	$24,080.00	5,188	4
2025-09-23	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	2,407	8.00	$19,256.00	7,596	4
2024-09-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	500	16.33	$8,165.00	6,781	4
2024-08-19	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	500	15.00	$7,500.00	6,781	4
2024-07-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,750	27.11	$47,442.50	6,781	4
2024-07-11	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,996	25.00	$49,900.00	6,781	4
2024-07-10	Kirn, David	Director,Officer	Chief Executive Officer	Direct	Sale	12,923	22.49	$290,638.27	1,059,153	4
2024-07-01	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	4,248	21.36	$90,737.28	1,737	4
2024-06-24	Kirn, David	Director,Officer	Chief Executive Officer	Direct	Sale	12,930	23.10	$298,683.00	1,059,153	4
2024-06-17	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,750	23.71	$41,492.50	1,737	4
2024-05-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,750	25.54	$44,695.00	1,737	4
2024-04-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,750	25.74	$45,045.00	1,737	4
2024-04-01	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	8,153	31.78	$259,102.34	1,737	4
2024-03-27	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	5,833	35.04	$204,388.32	1,737	4
2024-03-18	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,750	31.27	$54,722.50	1,737	4
2024-02-27	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,909	30.00	$57,270.00	1,737	4
2024-02-16	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	1,750	27.67	$48,422.50	1,737	4
2024-02-08	Kirn, David	Director,Officer	Chief Executive Officer	Direct	Sale	92,001	27.13	$2,495,987.13	1,059,153	4
2024-02-08	Bizily, Scott	Officer	Chief Legal Officer	Direct	Sale	6,244	27.50	$171,710.00	1,737	4
2024-02-05	Kim, Robert Young	Officer	Chief Medical Officer	Direct	Sale	24,552	30.05	$737,787.60	1,043	4
2024-01-23	Kirn, David	Director,Officer	Chief Executive Officer	Direct	Sale	5,696	18.41	$104,863.36	1,151,154	4
2024-01-05	Kirn, David	Director,Officer	Chief Executive Officer	Direct	Sale	28,237	19.84	$560,222.08	1,156,850	4
2024-01-04	Viking, Global Opportunit…	TenPercentOwner	-	Indirect	Sale	540,000	19.53	$10,546,200.00	4,247,914	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

69.42%

Inst. Shares: 47,249,850

Shares Outstanding: 68,064,586

2025-12-31

91.81%

Inst. Shares: 53,184,400

Shares Outstanding: 57,930,180

2025-09-30

70.10%

Inst. Shares: 39,346,736

Shares Outstanding: 56,126,330

2025-06-30

70.71%

Inst. Shares: 39,544,648

Shares Outstanding: 55,927,091

2025-03-31

75.92%

Inst. Shares: 42,322,305

Shares Outstanding: 55,744,047

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	47,249,850	68,064,586	69.42%
2025-12-31	53,184,400	57,930,180	91.81%
2025-09-30	39,346,736	56,126,330	70.10%
2025-06-30	39,544,648	55,927,091	70.71%
2025-03-31	42,322,305	55,744,047	75.92%
2024-12-31	46,250,869	53,943,741	85.74%
2024-09-30	57,314,159	55,554,476	103.17%
2024-06-30	57,023,566	55,282,754	103.15%
2024-03-31	56,028,553	49,271,984	113.71%
2023-12-31	42,119,872	39,130,067	107.64%
2023-09-30	41,655,748	42,256,629	98.58%
2023-06-30	41,274,387	38,335,219	107.67%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

4D Molecular Therapeutics, Inc. (FDMT) — SEC Financial Statements & Analysis

4D Molecular Therapeutics, Inc. (FDMT) is a biological products, (no diagnostic substances) company, incorporated in DE. 4D Molecular Therapeutics, Inc. trades on Nasdaq as: FDMT. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), 4D Molecular Therapeutics, Inc. reported a 278712.12% year-over-year revenue growth, a Debt-to-Equity ratio of 0.21x, a Price-to-Sales (P/S) ratio of 10.16x (TTM), a Price-to-Book (P/B) ratio of 2.29x (TTM), at a market cap of $934.62M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 278712.12%
Debt To Equity: 0.21x
P/S TTM: 10.16x
P/B TTM: 2.29x
Market Cap: $934.62M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is 4D Molecular Therapeutics, Inc. in?

4D Molecular Therapeutics, Inc. (FDMT) operates in the Biological Products, (No Diagnostic Substances) industry.

What is FDMT's market cap?

4D Molecular Therapeutics, Inc. (FDMT) has a market capitalization of $934.62M as of 2026-06-30.

What exchange does FDMT trade on?

4D Molecular Therapeutics, Inc. (FDMT) trades on the Nasdaq.

Where is 4D Molecular Therapeutics, Inc. incorporated?

4D Molecular Therapeutics, Inc. is incorporated in DE.